文档介绍：CAST: Cardiac Arrhythmia Suppression Trial
Purpose
To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic ventricular arrhythmias after MI reduces mortality due to arrhythmia
Reference
The CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406–12.
天马行空官方博客:http://t./tmxk_docin ;QQ:1318241189;QQ群:175569632
CAST: Cardiac Arrhythmia Suppression Trial - TRIAL DESIGN -
Design
Multicenter, multinational; initial phase open; main phase randomized, double-blind, placebo-controlled
Patients
1725 patients with >6 ventricular premature depolarizations/h (24h Holter recording) and left ventricular ejection fraction < at <90 days after MI or < at >90 days after MI
Follow up and primary end point
Mean 10 months follow up. Primary endpoint death from arrhythmia
Treatment
Open titration phase (mean 15 days) to select patients in whom drug (encainide, flecainide or moricizine) suppressed arrhythmias
Selected patients then randomized to three-times daily placebo, encainide 35–50 mg, flecainide 100 mg or moricizine 200–250 mg (results for moricizine not reported here)
CAST: Cardiac Arrhythmia Suppression Trial - RESULTS -
Study of encainide/flecainide vs. placebo halted at mean fo